Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Neurocrine Biosciences Inc (NASDAQ: NBIX) announces topline data from Phase 2 INTERACT study evaluating luvadaxistat (NBI-1065844/TAK-831) for the treatment of negative symptoms and cognitive impairment associated with schizophrenia.
- Luvadaxistat is an oral, selective inhibitor with a high binding affinity to d-amino acid oxidase. It targets glutamate, an abundant neurotransmitter in the brain.
- The trial did not meet its primary endpoint as measured by the change from baseline on the PANSS NSFS (score used to assess schizophrenia symptom severity) at Day 84.
- Luvadaxistat met secondary endpoints of cognitive assessment.
- Takeda Pharmaceutical Co Ltd (NYSE: TAK) granted an exclusive license to Neurocrine Biosciences for seven pipeline programs, including luvadaxistat, in June last year.
- The results from the study are being evaluated to determine the next steps for development activities.
- Price Action: TAK shares are up 1.88% at $17.30, while NBIX shares are down by 5.03% at $103.93 in the pre-market session on the last check Tuesday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!